Variation in Human Cytochrome P-450 Drug-Metabolism Genes: A Gateway to the Understanding of Plasmodium vivax Relapses

Although Plasmodium vivax relapses are classically associated with hypnozoite activation, it has been proposed that a proportion of these cases are due to primaquine (PQ) treatment failure caused by polymorphisms in cytochrome P-450 2D6 (CYP2D6). Here, we present evidence that CYP2D6 polymorphisms are implicated in PQ failure, which was reinforced by findings in genetically similar parasites, and may explain a number of vivax relapses. Using a computational approach, these polymorphisms were predicted to affect the activity of CYP2D6 through changes in the structural stability that could lead to disruption of the PQ-enzyme interactions. Furthermore, because PQ is co-administered with chloroquine (CQ), we investigated whether CQ-impaired metabolism by cytochrome P-450 2C8 (CYP2C8) could also contribute to vivax recurrences. Our results show that CYP2C8-mutated patients frequently relapsed early (<42 days) and had a higher proportion of genetically similar parasites, suggesting the possibility of recrudescence due to CQ therapeutic failure. These results highlight the importance of pharmacogenetic studies as a tool to monitor the efficacy of antimalarial therapy.

[1]  D. Caridha,et al.  The metabolism of primaquine to its active metabolite is dependent on CYP 2D6 , 2013, Malaria Journal.

[2]  W. Rojas,et al.  High genetic polymorphism of relapsing P. vivax isolates in northwest Colombia , 2011, Acta Tropica.

[3]  F. Nosten,et al.  The First Plasmodium vivax Relapses of Life Are Usually Genetically Homologous , 2011, The Journal of infectious diseases.

[4]  Douglas E. V. Pires,et al.  Protein-Protein Interactions: Structures and Druggability , 2015 .

[5]  W. Collins,et al.  Studies on the characterization of plasmodium vivax strains from Central America. , 1972, The American journal of tropical medicine and hygiene.

[6]  U. Meyer,et al.  Multiple mutations of the human cytochrome P450IID6 gene (CYP2D6) in poor metabolizers of debrisoquine. Study of the functional significance of individual mutations by expression of chimeric genes. , 1990, The Journal of biological chemistry.

[7]  A. Kleinman,et al.  Primaquine Failure and Cytochrome P-450 2D6 in Plasmodium vivax Malaria , 2013 .

[8]  Rafael Najmanovich,et al.  ENCoM server: exploring protein conformational space and the effect of mutations on protein function and stability , 2015, Nucleic Acids Res..

[9]  Douglas E. V. Pires,et al.  In silico functional dissection of saturation mutagenesis: Interpreting the relationship between phenotypes and changes in protein stability, interactions and activity , 2016, Scientific Reports.

[10]  M. Eichelbaum,et al.  Impaired expression of CYP2D6 in intermediate metabolizers carrying the *41 allele caused by the intronic SNP 2988G>A: evidence for modulation of splicing events , 2006, Pharmacogenetics and genomics.

[11]  Douglas E. V. Pires,et al.  Germline Mutations in the CDKN2B Tumor Suppressor Gene Predispose to Renal Cell Carcinoma. , 2015, Cancer discovery.

[12]  Q. Bassat,et al.  Strategies for Understanding and Reducing the Plasmodium vivax and Plasmodium ovale Hypnozoite Reservoir in Papua New Guinean Children: A Randomised Placebo-Controlled Trial and Mathematical Model , 2015, PLoS medicine.

[13]  N. White,et al.  The activation of vivax malaria hypnozoites by infectious diseases. , 2013, The Lancet. Infectious diseases.

[14]  J. Rubio,et al.  Estimation of the Antirelapse Efficacy of Tafenoquine, Using Plasmodium vivax Genotyping , 2015, The Journal of infectious diseases.

[15]  B. Tekwani,et al.  Differential CYP 2D6 Metabolism Alters Primaquine Pharmacokinetics , 2015, Antimicrobial Agents and Chemotherapy.

[16]  Ludevit Kadasi,et al.  Twelve novel HGD gene variants identified in 99 alkaptonuria patients: focus on ‘black bone disease’ in Italy , 2015, European Journal of Human Genetics.

[17]  Douglas E. V. Pires,et al.  Analysis of HGD Gene Mutations in Patients with Alkaptonuria from the United Kingdom: Identification of Novel Mutations. , 2015, JIMD reports.

[18]  Thomas A. Smith,et al.  How Much Remains Undetected? Probability of Molecular Detection of Human Plasmodia in the Field , 2011, PloS one.

[19]  Richard J Sciotti,et al.  CYP450 phenotyping and accurate mass identification of metabolites of the 8-aminoquinoline, anti-malarial drug primaquine , 2012, Malaria Journal.

[20]  M. Ingelman-Sundberg,et al.  Update on allele nomenclature for human cytochromes P450 and the Human Cytochrome P450 Allele (CYP-allele) Nomenclature Database. , 2013, Methods in molecular biology.

[21]  M. Hutz,et al.  Distribution of CYP2D6 Alleles and Phenotypes in the Brazilian Population , 2014, PloS one.

[22]  Tom L. Blundell,et al.  Flexibility and small pockets at protein–protein interfaces: New insights into druggability , 2015, Progress in biophysics and molecular biology.

[23]  Lena Huldén,et al.  Activation of the hypnozoite: a part of Plasmodium vivax life cycle and survival , 2011, Malaria Journal.

[24]  L. Teh,et al.  Pharmacogenomics of CYP2D6: molecular genetics, interethnic differences and clinical importance. , 2012, Drug metabolism and pharmacokinetics.

[25]  U. d’Alessandro,et al.  Plasmodium vivax Sub-Patent Infections after Radical Treatment Are Common in Peruvian Patients: Results of a 1-Year Prospective Cohort Study , 2011, PloS one.

[26]  J. Rubio,et al.  Tafenoquine treatment of Plasmodium vivax malaria: suggestive evidence that CYP2D6 reduced metabolism is not associated with relapse in the Phase 2b DETECTIVE trial , 2016, Malaria Journal.

[27]  Jukka Corander,et al.  CYP2D6 worldwide genetic variation shows high frequency of altered activity variants and no continental structure , 2007, Pharmacogenetics and genomics.

[28]  G. Paganotti,et al.  Human genetic variation is associated with Plasmodium falciparum drug resistance. , 2011, The Journal of infectious diseases.

[29]  B. Craige,et al.  The Chesson strain of Plasmodium vivax malaria; relationship between prepatent period, latent period and relapse rate. , 1947, The Journal of infectious diseases.

[30]  U. d’Alessandro,et al.  High Complexity of Plasmodium vivax Infections in Symptomatic Patients from a Rural Community in Central Vietnam Detected by Microsatellite Genotyping , 2010, The American journal of tropical medicine and hygiene.

[31]  Q. Bassat,et al.  Relapses contribute significantly to the risk of Plasmodium vivax infection and disease in Papua New Guinean children 1-5 years of age. , 2012, The Journal of infectious diseases.

[32]  M. Davenport,et al.  Modeling the Dynamics of Plasmodium vivax Infection and Hypnozoite Reactivation In Vivo , 2015, PLoS neglected tropical diseases.

[33]  R. Price,et al.  Multidrug-Resistant Plasmodium vivax Associated with Severe and Fatal Malaria: A Prospective Study in Papua, Indonesia , 2008, PLoS medicine.

[34]  O. Augusto,et al.  Hydroxylated metabolites of the antimalarial drug primaquine. Oxidation and redox cycling. , 1992, The Journal of biological chemistry.

[35]  R. Noviyanti,et al.  The clinical and public health problem of relapse despite primaquine therapy: case review of repeated relapses of Plasmodium vivax acquired in Papua New Guinea , 2014, Malaria Journal.

[36]  P. Garnham,et al.  Plasmodium cynomolgi: x-irradiation and development of exo-erythrocytic schizonts in Macaca mulatta. , 1970, Experimental parasitology.

[37]  Q. Bassat,et al.  Postmortem characterization of patients with clinical diagnosis of Plasmodium vivax malaria: to what extent does this parasite kill? , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[38]  Douglas E. V. Pires,et al.  DUET: a server for predicting effects of mutations on protein stability using an integrated computational approach , 2014, Nucleic Acids Res..

[39]  Estimates of adherence to treatment of vivax malaria , 2014, Malaria Journal.

[40]  Douglas E. V. Pires,et al.  Platinum: a database of experimentally measured effects of mutations on structurally defined protein–ligand complexes , 2014, Nucleic Acids Res..

[41]  M Ingelman-Sundberg,et al.  Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity , 2005, The Pharmacogenomics Journal.

[42]  P. Beaune,et al.  In vitro metabolism of chloroquine: identification of CYP2C8, CYP3A4, and CYP2D6 as the main isoforms catalyzing N-desethylchloroquine formation. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[43]  J. Carlton,et al.  Relapses of Plasmodium vivax infection usually result from activation of heterologous hypnozoites. , 2007, The Journal of infectious diseases.

[44]  Douglas E. V. Pires,et al.  mCSM: predicting the effects of mutations in proteins using graph-based signatures , 2013, Bioinform..

[45]  E. A. Pereira,et al.  Adherence to Plasmodium vivax malaria treatment in the Brazilian Amazon Region , 2011, Malaria Journal.

[46]  R. Price,et al.  Global extent of chloroquine-resistant Plasmodium vivax: a systematic review and meta-analysis , 2014, The Lancet. Infectious diseases.

[47]  Ji-Young Park,et al.  Cytochrome P450 2C8 and CYP3A4/5 are involved in chloroquine metabolism in human liver microsomes , 2003, Archives of pharmacal research.

[48]  L. H. Carvalho,et al.  Multiple-Clone Activation of Hypnozoites Is the Leading Cause of Relapse in Plasmodium vivax Infection , 2012, PloS one.

[49]  Suradi,et al.  Diagnosis of resistance to chloroquine by Plasmodium vivax: timing of recurrence and whole blood chloroquine levels. , 1997, The American journal of tropical medicine and hygiene.

[50]  Douglas E. V. Pires,et al.  pkCSM: Predicting Small-Molecule Pharmacokinetic and Toxicity Properties Using Graph-Based Signatures , 2015, Journal of medicinal chemistry.

[51]  Eric F. Johnson,et al.  Contributions of Ionic Interactions and Protein Dynamics to Cytochrome P450 2D6 (CYP2D6) Substrate and Inhibitor Binding* , 2015, The Journal of Biological Chemistry.